Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis.
Adult
Age Factors
Aged
Aged, 80 and over
Asian People
Body Mass Index
Bone Density
Cross-Sectional Studies
Female
Glucocorticoids
/ adverse effects
Humans
Japan
/ epidemiology
Logistic Models
Middle Aged
Osteoporosis
/ chemically induced
Pelvic Bones
/ metabolism
Retrospective Studies
Rheumatic Diseases
/ complications
Risk Factors
Sex Factors
Spinal Fractures
/ epidemiology
Bone mineral density
Glucocorticoid
Osteoporosis
Rheumatological disease
Vertebral fracture
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
29 Jul 2020
29 Jul 2020
Historique:
received:
20
05
2020
accepted:
22
07
2020
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
29
4
2021
Statut:
epublish
Résumé
Glucocorticoid-induced osteoporosis and vertebral fracture are common complications in patients on glucocorticoid treatment for rheumatological diseases. The present study aimed to identify the risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis. This study included 225 Japanese women with glucocorticoid-induced osteoporosis and 72 patients with postmenopausal osteoporosis. All participants were treated with bisphosphonate or denosumab for osteoporosis with active form of vitamin D for at least 3 years. The differences of clinical parameters, including age, disease duration, body mass index (BMI), bone mineral density (BMD), and the dose and treatment duration of glucocorticoid were assessed between patients with and without vertebral fracture. Multivariate logistic regression analysis was also performed to evaluate the association of vertebral fracture with clinical parameters. The significant differences related to age, BMD of the hip, disease duration, glucocorticoid treatment duration between patients with and without vertebral fractures were demonstrated. The present study indicated that disease duration, BMI, and the total hip BMD were independent risk factors for vertebral fractures in patients with glucocorticoid-induced osteoporosis. Prolonged disease duration, low BMI, and low total hip BMD could be risk factors of vertebral fracture in patients on glucocorticoid treatment for rheumatological diseases.
Sections du résumé
BACKGROUND
BACKGROUND
Glucocorticoid-induced osteoporosis and vertebral fracture are common complications in patients on glucocorticoid treatment for rheumatological diseases. The present study aimed to identify the risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis.
METHODS
METHODS
This study included 225 Japanese women with glucocorticoid-induced osteoporosis and 72 patients with postmenopausal osteoporosis. All participants were treated with bisphosphonate or denosumab for osteoporosis with active form of vitamin D for at least 3 years. The differences of clinical parameters, including age, disease duration, body mass index (BMI), bone mineral density (BMD), and the dose and treatment duration of glucocorticoid were assessed between patients with and without vertebral fracture. Multivariate logistic regression analysis was also performed to evaluate the association of vertebral fracture with clinical parameters.
RESULTS
RESULTS
The significant differences related to age, BMD of the hip, disease duration, glucocorticoid treatment duration between patients with and without vertebral fractures were demonstrated. The present study indicated that disease duration, BMI, and the total hip BMD were independent risk factors for vertebral fractures in patients with glucocorticoid-induced osteoporosis.
CONCLUSIONS
CONCLUSIONS
Prolonged disease duration, low BMI, and low total hip BMD could be risk factors of vertebral fracture in patients on glucocorticoid treatment for rheumatological diseases.
Identifiants
pubmed: 32727595
doi: 10.1186/s13018-020-01813-4
pii: 10.1186/s13018-020-01813-4
pmc: PMC7391489
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
290Références
Arthritis Rheum. 2001 Jan;44(1):202-11
pubmed: 11212161
Rheumatology (Oxford). 2000 Dec;39(12):1383-9
pubmed: 11136882
J Bone Miner Metab. 2005;23(2):105-9
pubmed: 15750687
Osteoporos Int. 2016 Nov;27(11):3239-3249
pubmed: 27273113
N Engl J Med. 2007 Nov 15;357(20):2028-39
pubmed: 18003959
Lancet. 2009 Apr 11;373(9671):1253-63
pubmed: 19362675
Arthritis Care Res (Hoboken). 2013 Feb;65(2):294-8
pubmed: 22807233
Rheumatology (Oxford). 2007 Jul;46(7):1185-90
pubmed: 17500075
Calcif Tissue Int. 2000 Oct;67(4):277-85
pubmed: 11000340
J Rheumatol. 2009 Aug;36(8):1646-52
pubmed: 19605677
Arthritis Rheumatol. 2019 Jul;71(7):1174-1184
pubmed: 30816640
Osteoporos Int. 2004 Sep;15(9):724-8
pubmed: 14997287
J Bone Miner Metab. 2017 Jan;35(1):52-57
pubmed: 26369319
J Clin Densitom. 2019 Jan - Mar;22(1):25-30
pubmed: 29729949
Arthritis Rheum. 2009 Nov;60(11):3346-55
pubmed: 19877063
Gerontol Geriatr Med. 2020 Mar 25;6:2333721420914771
pubmed: 32232115
Osteoporos Int. 2002 Oct;13(10):777-87
pubmed: 12378366
Osteoporos Int. 2014 Apr;25(4):1275-83
pubmed: 24297094
Arthritis Rheum. 2003 Nov;48(11):3224-9
pubmed: 14613287
Arthritis Rheum. 2007 Jun;56(6):1966-73
pubmed: 17530722
J Bone Miner Metab. 2013 May;31(3):247-57
pubmed: 23553500
Osteoporos Int. 2004 Apr;15(4):323-8
pubmed: 14762652
Osteoporos Int. 2013 Sep;24(9):2493-8
pubmed: 23572142
Osteoporos Int. 2016 May;27(5):1709-18
pubmed: 26694595
Intern Med. 2011;50(22):2793-800
pubmed: 22082891
Bone. 2006 Aug;39(2):253-9
pubmed: 16574519
Ther Adv Musculoskelet Dis. 2019 Sep 20;11:1759720X19876468
pubmed: 31565078
N Engl J Med. 1998 Jul 30;339(5):292-9
pubmed: 9682041
J Orthop. 2018 Jan 31;15(1):89-93
pubmed: 29657446
Arthritis Rheum. 2007 Jan;56(1):208-14
pubmed: 17195223
Osteoporos Int. 2012 Sep;23(9):2257-76
pubmed: 22434203
J Bone Miner Res. 2000 Jun;15(6):1006-13
pubmed: 10841169